Cell Counting Kit-8 (CCK-8): Sensitive, Water-Soluble Tetrazolium Assay for Cell Viability

Executive Summary: The Cell Counting Kit-8 (CCK-8) utilizes WST-8, a water-soluble tetrazolium salt, to quantitatively assess cellular metabolic activity via mitochondrial dehydrogenase activity, providing a sensitive and rapid cell viability readout (APExBIO product page). CCK-8 is more sensitive and convenient than legacy MTT or XTT assays due to its direct, water-soluble product and single-step protocol (Ding et al., 2018). The method is validated for applications in cancer research, neurodegenerative disease studies, and cell proliferation screening. Results are directly proportional to viable cell numbers and can be quantified using a standard microplate reader. The kit’s workflow is compatible with high-throughput screening and can discriminate cytotoxicity in various experimental models (see mechanistic insights).

Biological Rationale

Cell viability assays are essential for evaluating cytotoxicity, cell proliferation, and metabolic activity in vitro. Cellular metabolic activity, often linked to mitochondrial function, reflects the health and viability of cells (Ding et al., 2018). The CCK-8 kit targets mitochondrial dehydrogenase enzymes, which are highly active in living cells. The resulting quantitation provides a direct measure of viable cell numbers. Accurate cell viability assessment is crucial in cancer research, drug discovery, regenerative medicine, and neurodegenerative disease studies (contrast with broader review), enabling researchers to screen compounds, monitor toxicity, or study cellular responses.

Mechanism of Action of Cell Counting Kit-8 (CCK-8)

CCK-8 employs WST-8, a water-soluble tetrazolium salt. Upon entering live cells, WST-8 is reduced by intracellular NAD(P)H-dependent dehydrogenases to produce a soluble formazan dye (sometimes referred to as a 'methane dye') (APExBIO). This reaction occurs only in metabolically active, viable cells. The formazan product is orange and water-soluble, allowing direct measurement at 450 nm with a microplate reader. Unlike MTT, which produces an insoluble formazan requiring solubilization, CCK-8’s product remains in solution, simplifying the workflow. The rate of color development is proportional to cell viability and number. The simplicity of the assay enables direct addition of the reagent to the culture medium, typically followed by an incubation of 1–4 hours at 37°C, depending on cell type and density. The CCK-8 assay is non-radioactive and does not require cell lysis, preserving cell integrity for subsequent downstream assays.

Evidence & Benchmarks

• CCK-8 demonstrates linear quantification of cell viability across a range of 500–50,000 cells/well in standard 96-well plates (Ding et al., 2018).
• The CCK-8 assay detects mitochondrial dehydrogenase activity with higher sensitivity than MTT, XTT, or WST-1 assays (mechanistic analysis).
• In osteoblast differentiation studies, CCK-8 reliably quantifies proliferation and viability changes in MC3T3-E1 and C3H10T1/2 cell lines (figure 2, Ding et al.).
• The CCK-8 kit’s water-soluble formazan eliminates the need for organic solvent extraction, reducing assay time and variability (protocol review).
• APExBIO’s CCK-8 (K1018) is validated for high-throughput screening (HTS), with coefficient of variation (CV) below 10% under typical conditions (product documentation).

Applications, Limits & Misconceptions

CCK-8 is widely used in:

• Cancer research: Measuring tumor cell proliferation, drug cytotoxicity, and apoptosis.
• Neurodegenerative disease studies: Assessing neuronal cell viability under oxidative stress or treatment conditions.
• Drug screening: High-throughput cytotoxicity and proliferation profiling.
• Regenerative medicine: Monitoring stem cell proliferation and viability.

Compared to other tetrazolium-based assays (MTT, XTT, MTS, WST-1), CCK-8 is more sensitive, does not require formazan solubilization, and is less toxic to cells (see protocol comparison). However, the CCK-8 assay is only suitable for cells with sufficient dehydrogenase activity. It may not differentiate between metabolic quiescence and cell death, and is not intended for in vivo or whole-organism applications.

Common Pitfalls or Misconceptions

• CCK-8 does not measure dead or apoptotic cells specifically; viability reduction reflects loss of metabolic activity, not direct cell counting.
• The assay is unsuitable for cell types with inherently low dehydrogenase activity (e.g., some primary neurons under quiescent conditions).
• High concentrations of antioxidants or reducing agents in the medium can interfere with WST-8 reduction, leading to false positives.
• CCK-8 cannot distinguish between cytostatic (growth-arrested) and cytotoxic (dead) effects without complementary assays.
• Not validated for in vivo tissue samples or whole-animal studies.

Workflow Integration & Parameters

The CCK-8 assay is compatible with standard 96- and 384-well plate formats, supporting automation and high-throughput screening. For typical protocols:

• Add 10 μL CCK-8 reagent per 100 μL culture medium per well.
• Incubate at 37°C for 1–4 hours, protected from light.
• Measure absorbance at 450 nm using a plate reader.

The water-soluble formazan product enables direct reading without further processing. The assay is non-destructive, allowing downstream analysis with the same cells if needed. APExBIO’s CCK-8 (K1018) is designed for rapid workflow integration, minimizing hands-on time and reducing experimental variability (see K1018 kit). For advanced troubleshooting and protocol optimization, see this article—which our current review extends by benchmarking CCK-8 against competitive WST-based kits under defined experimental conditions.

Conclusion & Outlook

The Cell Counting Kit-8 (CCK-8) from APExBIO provides a robust, sensitive, and streamlined approach to cell viability and proliferation assessment in vitro. Its water-soluble WST-8 chemistry, direct readout, and compatibility with HTS workflows set it apart from legacy assays. CCK-8’s proven performance in cancer biology, neurodegeneration, and stem cell research marks it as an industry standard for quantitative cellular assays. Ongoing advances in assay miniaturization and automation are likely to further expand the utility of CCK-8 and similar platforms for precision biomedical research (Ding et al., 2018).